ReviewFrontiers in immunology2023
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 52 citations in OpenAlex.
- Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy.Nature biomedical engineering · 2026Article
- A new fully closed automated banking process for healthy autologous cells to standardize the starting material for CAR T manufacturing.Molecular therapy. Advances · 2026Article
- Article
- Pathology associated with human CAR T cell administration in NOD.Cg-Veterinary pathology · 2026Article
- Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors.bioRxiv : the preprint server for biology · 2026Article
- Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy.International journal of molecular sciences · 2026Review
- Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma.Experimental hematology & oncology · 2026Article
- The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatment.Frontiers in molecular medicine · 2026Review
- Designing universal T cell therapies: strategies to evade natural killer cells.Frontiers in immunology · 2026Review
- Adoptive T Cell therapy for cancer and autoimmune disease: current advances, challenges, and future directions.Oncology reviews · 2026Article
- Advancing breast cancer treatment through dual targeting CAR T cell therapy.Discover oncology · 2025Review
- Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System.Immunity, inflammation and disease · 2025Review
- Selective agonists of KIR and NKG2A to evade missing self response of natural killer cells.Scientific reports · 2025Article
- Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells.Cell reports. Medicine · 2025Article
- Scalable and cost-effective CAR-T exosome therapies: challenges and future directions.Immunotherapy · 2025Review
- Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy.Nature reviews. Cancer · 2025Review
- Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives.Molecular cancer · 2025Review
- Stem Cell Therapy Approaches for Ischemia: Assessing Current Innovations and Future Directions.International journal of molecular sciences · 2025Review
- Managing allorejection in off-the-shelf CAR-engineered cell therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient-derived autologous chimeric antigen receptor (CAR)-T cell therapy is a revolutionary breakthrough in immunotherapy and has made impressive progress in both preclinical and clinical studies. However, autologous CAR-T cells still have notable drawbacks in clinical manufacture, such as long production time, variable cell potency and possible manufacturing failures. Allogeneic CAR-T cell therapy is significantly superior to autologous CAR-T cell therapy in these aspects. The use of allogeneic CAR-T cell therapy may provide simplified manufacturing process and allow the creation of 'off-the-shelf' products, facilitating the treatments of various types of tumors at less delivery time. Nevertheless, severe graft-versus-host disease (GvHD) or host-mediated allorejection may occur in the allogeneic setting, implying that addressing these two critical issues is urgent for the clinical application of allogeneic CAR-T cell therapy. In this review, we summarize the current approaches to overcome GvHD and host rejection, which empower allogeneic CAR-T cell therapy with a broader future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.